Prof Jeanne Tie
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
353 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
Liquid Biopsy in Biliary Tract Cancer: When Tissue Is Not Enough.
DOI: 10.1158/1078-0432.CCR-26-20902026
Journal article
A Phase I Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients with Advanced Gastrointestinal Cancers.
DOI: 10.1158/2767-9764.CRC-26-01012026
Journal article
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.
DOI: 10.1093/jnci/djag2912026
Journal article
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
DOI: 10.5694/mja2.702662026
Journal article
Artificial Intelligence-Assisted Risk Stratification in Stage II Colorectal Cancer: Multi-Institutional Validation of Semantically Enhanced Deep Learning.
DOI: 10.1053/j.gastro.2026.07.0092026
Journal article
7RO Molecular correlates of enhanced outcome with first-line (1L) encorafenib cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study
DOI: 10.1016/j.annonc.2026.05.0112026
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Colorectal Cancer Through Liquid Biopsy
RECENT SCHOLARLY WORKS
2026
Journal article
114P Phase I/Ib study of divarasib (DIVA) cetuximab (CETUX) ± FOLFOX for KRAS G12C-mutated (mut) metastatic colorectal cancer (mCRC)
DOI: 10.1016/j.annonc.2026.05.1152026
Journal article
Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
DOI: 10.1200/jco.2026.44.16_suppl.41012026
Journal article
Late-line Systemic Therapy in Metastatic Colorectal Cancer: A Narrative Review and Australian Expert Perspective
DOI: 10.1016/j.clcc.2026.04.0012026
Journal article
Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
DOI: 10.1200/jco.2026.44.16_suppl.tps3675